Congenital hereditary endothelial dystrophy (CHED) is a rare genetic corneal disorder causing progressive cornea clouding and significant visual impairment. CHED remains a leading indication for pediatric corneal transplantation despite its infrequency, particularly in regions with high consanguinity rates like Southeast Asia. Identifying the Solute Carrier Family 4 Member 11 (SLC4A11) gene as the genetic basis of CHED has led to the discovery of it's various genetic variations. However, a comprehensive understanding of its clinical-genetic correlation, pathophysiology, and optimal management is ongoing. This review aims to consolidate current knowledge about CHED, covering its genetic origins, pathophysiological mechanisms, clinical presentation, and management strategies. Surgical intervention, such as penetrating keratoplasty (PK), Descemet stripping automated endothelial keratoplasty (DSAEK), and Descemet membrane endothelial keratoplasty (DMEK), remains the primary treatment. DSAEK and DMEK offer advantages over PK, including quicker visual recovery, reduced complications, and longer graft survival, especially in the pediatric age group. The timing of surgical interventions depends on disease severity, age at presentation, comorbidities, and visual potential. Elevated oxidative stress in CHED corneal tissue suggests potential benefits from anti-inflammatory drugs to rescue mutated endothelial cells. Considering the limitations of corneal graft surgeries, exploring novel gene-based molecular therapies are essential for future management. Early diagnosis, appropriate surgical interventions, amblyopia control, and genetic counseling for predictive analysis are pivotal for optimizing CHED management. A multidisciplinary approach involving ophthalmologists, researchers, and genetic counselors is essential for precise diagnosis and optimal care for CHED patients.
Purpose: Rho-associated protein kinase inhibitor ripasudil 0.4% has been approved for clinical use in glaucoma to reduce intraocular pressure. The purpose is to evaluate the effect of ripasudil on normal corneal endothelium. Materials and Methods: This prospective observational study included 14 healthy volunteers. After a baseline specular microscopy, a single drop of ripasudil was instilled in one eye of every subject. Serial specular microscopy was performed after 1, 3, 6, and 24 h. The endothelial cell morphology and quantitative parameters were evaluated. The untreated fellow eyes served as controls. Results: Mean age was 31.0 ± 5.8 years. There were statistically significant changes in the mean number of endothelial cells, endothelial cell density, average cell size, coefficient of variation, and hexagonality. Significant differences between study and control eyes were observed in all quantitative parameters at 1 h and/or 3 h after ripasudil administration. The study and control eyes were comparable at baseline, 6, and 24 h. The characteristic morphological alterations noted in the study eyes were dark–light reversal patterns along with dark or dropout areas. Compared to baseline, there was a significant increase (P < 0.001) in the area of endothelial morphological alterations (90%) at 1 h, which decreased to 10% in 3 h and reached 0% by 6 and 24 h. Conclusion: Specular microscopy revealed significant changes in quantitative parameters after ripasudil administration. Transient morphological changes were observed lasting up to 3 h in some eyes that reverted to normal. It is important to be familiar with temporal alterations in endothelial cell imaging in those using ripasudil.
Genomic testing may provide individuals and families with information on the nature, mode of inheritance, and how test results may help them make informed medical and personal decisions. This commentary provides the clinician's perspective with genetic risk assessment, family history, and genetic testing to clarify the genetic status of family members. It is not meant to address all personal, cultural, or ethical issues that may arise or substitute for consultation with a genetics professional.[1] Anterior segment dysgeneses (ASD) encompasses a broad spectrum of developmental abnormalities that contributes to a substantial burden of childhood corneal blindness in many consanguineous populations worldwide, including India. ASD affects multiple anatomical structures of the eye, including the cornea, iris, sclera, ciliary body and aqueous outflow pathways, exhibiting different phenotypes with overlapping clinical features in the disease spectrum.[2] The pathogenesis of ASD is multifactorial and includes sporadic, environmental, and genetic factors or is related to intrauterine infections. ASD demonstrates different modes of inheritance and a high degree of inter- and intra-familial phenotypic variability. Therefore, the patient receiving a molecular diagnosis has a distinct advantage: an end to the diagnostic odyssey, determination of prognosis and clarification of treatment, access to proper genetic counseling, and confirming eligibility for clinical trials or genetic-specific therapies.[123] A review by Arif et al.[4] provides the rationale for genetic testing in ASD. The review discusses the benefits of precise diagnosis by genomic methods in anterior segment disorders, which helps in providing accurate prognosis, assists in genetic counseling and prenatal diagnosis, and helps patients to participate in potential gene-specific therapeutic trials. Prerequisites for a successful outcome of a genomic screening are an accurate clinical diagnosis, a careful family pedigree that guides focused genetic testing, and genetic counseling (both pre-test and post-test). Therefore, it is crucial to classify phenotypes accurately based on anterior segment features, and these findings should be corroborated using an appropriate anterior segment imaging that helps determine valid genotype–phenotype correlations accurately.[2] Recent advancement in molecular biology and genomics, and its application in translational health science has enabled the discovery of genes and mutations involved in ASD. Genomic testing assesses many genes in one test. It is often used to diagnose heterogeneous single gene disorders where pathogenic variation in one of many genes is known to cause similar phenotypes or where a clinical diagnosis is difficult to reach. Genomic testing can diagnose several diseases in the ophthalmic setting, including inherited retinal dystrophies, pediatric cataracts, glaucoma, anterior segment dysgenesis, and other syndromic developmental disorders with eye involvement. The testing can encompass several modalities ranging from whole-genome sequencing to exome sequencing or targeted gene panels. The advantages to the patient of receiving a molecular diagnosis include an end to the diagnostic odyssey, determination of prognosis and clarification of treatment, access to proper genetic counseling, and confirming eligibility for clinical trials or genetic-specific therapies. Genomic testing is a powerful addition to diagnosing and managing inherited eye disease.[2345] A protocol for genetic testing is presented. If specific mutations in a gene are common, they should be the first-tier test, such as the mutations in PAX6. If mutations in one gene are likely, sequencing of that gene should be carried out; for example, genes like PAX6 in Aniridia, PITX2, FOXC1 in Axenfeld-Rieger Syndrome, PAX6, PITX2, CYP1B1, FOXC, B3GALTL in Peters anomaly, and FOXE3 in congenital primary aphakia. Such an approach is helpful for their characterization of the genotype. On the other hand, the disorders with genetic heterogeneity require multi-gene panel tests, and if these tests show no abnormality, then deletion or duplication or microarray studies are recommended, followed in sequence by clinical exome sequencing (5000 to 6000 genes), whole-exome sequencing (about 20,000 genes, or whole-genome studies (includes all introns). Despite numerous advances, phenotypic and genotypic heterogeneity pose continuing challenges to understand the mechanisms underlying the complexity of ASD. Genomic methods, such as genome-wide association studies, are potentially an effective tool to understand anterior segment dysgenesis and the individual's susceptibility to the development of ASD.[23456] Molecular cell biology and genetic analyses of congenital eye diseases have provided important information on the regulation of neural crest cells (NCCs) that play an important role in the development of the anterior segment of the eye. Nevertheless, a complete understanding of the NCC as a contributor to ocular development remains elusive. In addition, positional information during ocular NCC migration and the molecular pathways that regulate end tissue differentiation have yet to be fully elucidated. Furthermore, the clinical challenges of ocular diseases, such as Axenfeld-Rieger syndrome (ARS), Peters anomaly (PA), and primary congenital glaucoma (PCG), strongly suggest the need for better treatment. While several aspects of NCC evolution have recently been reviewed, this discussion will consolidate the most recent knowledge on the contributions of the NC in ocular development, especially the anterior segment, and the knowledge obtained from its clinical manifestations associated with diseases. This knowledge can ultimately inform translational discoveries with the potential for regenerative therapies.[7] Therefore, for an ophthalmologist, genetic testing should be as focused and ordered based on the specific phenotype and if testing will answer specific questions. Testing should be done by understanding its importance and limitations, and interpretation of analysis should be made along with a trained individual, such as a medical geneticist and a genetic counselor within ophthalmic and pediatric clinics are likely to improve the delivery of clinical care in these settings.
To report a case of spontaneous Descemet-membrane detachment in a patient with anterior megalophthalmos managed by intracameral perflouropropane (C3F8) gas instillation.Retrospective case review.A 12-year-old boy presented with spontaneous corneal edema in the left eye. The anterior segment findings were suggestive of anterior megalophthalmos. Slit-lamp examination of the left eye revealed a detached Descemet membrane superiorly. Anterior segment optical coherence tomography delineated the detached Descemet membrane. Descemetopexy with nonexpansile 14% perflouropropane (C3F8) gas resulted in rapid and complete resolution of corneal edema.Patients with anterior megalophthalmos can develop spontaneous detachment of Descemet membrane, which can be effectively managed by intracameral gas instillation.
To report the results of Descemet's stripping endothelial keratoplasty (DSEK) for failed therapeutic penetrating keratoplasty (PK).Twenty-seven eyes of 27 patients undergoing DSEK for failed therapeutic PK were analysed.The mean age of the patients was 36 ± 13.9 years (range: 14-70 years). The median size of the therapeutic graft was 10 mm (inter-quartile range; IQR 9.5-11 mm). Descemet's membrane stripping was performed in all eyes. Graft clarity was achieved in 20/27 eyes. Six eyes had primary graft failure, and one had interface keratitis in the early postoperative period. In all eyes with primary graft failure, there was progressive stromal vascularization, which led to haziness in the graft. Late postoperative complications were rejection in four eyes, infection in two eyes, secondary graft failure in one eye and vortex keratopathy in one eye. Graft size was found to be a significant risk factor for graft rejection in this series. At the last follow-up visit, the best-corrected visual acuity was ≥20/40 in 5/27 eyes (18.5%), 20/60-20/40 in 12/27 eyes (44.4%), 20/100-20/60 in 3/27 eyes (1.5%) and ≤20/200 in 7/27 eyes (25.9%).Considering the limited success of repeat PK in failed large therapeutic keratoplasty, DSEK is a viable option for visual rehabilitation in these eyes, however; visual acuity may be limited due to sub-epithelial/stromal or interface scarring.
'%3e%3ccircle r='20' fill='%23008'/%3e%3ccircle r='17.5' fill='%23fff'/%3e%3ccircle r='3.5' fill='%23008'/%3e%3cg id='d'%3e%3cg id='c'%3e%3cg id='b'%3e%3cg id='a' fill='%23008'%3e%3ccircle r='.875' transform='rotate(7.5 -8.75 133.5)'/%3e%3cpath d='M0 17.5.6 7 0 2l-.6 5L0 17.5z'/%3e%3c/g%3e%3cuse xlink:href='%23a' transform='rotate(15)'/%3e%3c/g%3e%3cuse xlink:href='%23b' transform='rotate(30)'/%3e%3c/g%3e%3cuse xlink:href='%23c' transform='rotate(60)'/%3e%3c/g%3e%3cuse xlink:href='%23d' transform='rotate(120)'/%3e%3cuse xlink:href='%23d' transform='rotate(-120)'/%3e%3c/g%3e%3c/svg%3e)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
'/%3e%3c/defs%3e%3cpath fill='%23012169' d='M0 0h10080v5040H0z'/%3e%3cpath stroke='%23fff' stroke-width='.6' d='m0 0 6 3m0-3L0 3' clip-path='url(%23b)' transform='scale(840)'/%3e%3cpath stroke='%23e4002b' stroke-width='.4' d='m0 0 6 3m0-3L0 3' clip-path='url(%23c)' transform='scale(840)'/%3e%3cpath stroke='%23fff' stroke-width='840' d='M2520 0v2520M0 1260h5040'/%3e%3cpath stroke='%23e4002b' stroke-width='504' d='M2520 0v2520M0 1260h5040'/%3e%3cg fill='%23fff'%3e%3cuse xlink:href='%23d' x='2520' y='3780'/%3e%3cuse xlink:href='%23a' x='7560' y='4200'/%3e%3cuse xlink:href='%23a' x='6300' y='2205'/%3e%3cuse xlink:href='%23a' x='7560' y='840'/%3e%3cuse xlink:href='%23a' x='8680' y='1869'/%3e%3cuse xlink:href='%23e' x='8064' y='2730'/%3e%3c/g%3e%3c/svg%3e)